HOME >> BIOLOGY >> NEWS
ECCO 13 explores issues in cancer patient management

Paris, France, Wednesday 2 November - New study findings showcased at the 13th European Cancer Conference (ECCO) have shed further light on the manifold factors which must be considered when managing patients with cancer. Studies from around Europe looked at a number of the issues faced by cancer patients and assessed their impact and associated implications.

Greek researchers undertook a study to assess the rates and clinical course of anxiety and depression in Greek patients with cancer scheduled to commence chemotherapy, and to investigate the factors which determined sufferers' overall quality of life. As the ECCO 13 audience was reminded, the onset of cancer is often accompanied by severe emotional distress, yet actual estimates of anxiety and depression vary considerably across different studies, ranging from a low of 1% to a high of almost 50%.

In total, 80 Greek patients completed questionnaires before and after chemotherapy treatment. Fatigue and sleep disturbances were significantly increased after the treatment period, but no changes emerged in the rates of anxiety or depression throughout chemotherapy. Nevertheless a significant proportion of the cancer patients studied (almost a third), were found to be experiencing severe emotional distress before, throughout and after chemotherapy. The presence of depression proved to be a strong predictor of overall quality of life. This study concluded that routine screening of emotional distress across all phases of cancer should be mandatory because it will contribute to identifying those patients in need of psychological or pharmaceutical intervention.

"The implication for practice relates to the proper screening and management of cancer patients with psychological distress", reported Dr Gregoris Iconomou study author from the University of Patras Medical School, Greece at ECCO 13. "Almost a third of our patients experienced levels of anxiety and depression sufficient to warrant further
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
2-Nov-2005


Page: 1 2 3

Related biology news :

1. NASA mission explores worlds deepest sinkhole
2. Book explores history, causes of allergy and asthma epidemic
3. Florida Tech explores microalgae for biofuel
4. New report explores nanotechnologys future
5. Neurophysiologist explores the mysteries of the human brain
6. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts
7. Williams College biologist explores photosynthetic apparatus
8. AAAS book explores evolution and Christianitys response
9. March issue of JADA explores saliva as diagnostic tool
10. Avian flu modeled on supercomputer, explores vaccine and isolation options for thwarting a pandemic
11. World congress explores research, multi-disciplinary science of soils

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ECCO explores issues cancer patient management

(Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: